ライフサイエンスコーパス: inverse agonist

1 RO-alpha (an agonist) but not with IP-10 (an inverse agonist).

2 o that of the highly stable ghrelin receptor inverse agonist.

3 sing JD5037, a peripherally restricted CB1 R inverse agonist.

4 racterize a T2R endogenous antagonist and an inverse agonist.

5 ghrelin receptor (GHSR1a) antagonist and an inverse agonist.

6 the growth plate, enabling ICI to act as an inverse agonist.

7 that is important for ORG27569 to act as an inverse agonist.

8 b) acted on the US28 receptor as a nontoxic, inverse agonist.

9 imonabant, the first clinically approved CB1 inverse agonist.

10 nal change in H5 and therefore it acts as an inverse agonist.

11 full agonists, two partial agonists, and an inverse agonist.

12 expressed salamander cone opsins, acting an inverse agonist.

13 otoswitchable tethered neutral antagonist or inverse agonist.

14 grelor has the pharmacological profile of an inverse agonist.

15 rally distinct from the first-generation CB1 inverse agonists.

16 tionality switch from agonist to antagonists/inverse agonists.

17 iors as full agonists, partial agonists, and inverse agonists.

18 forskolin-induced cAMP production acting as inverse agonists.

19 ologically confirmed as a new class of CB(2) inverse agonists.

20 ith efficacy but negative cooperativity with inverse agonists.

21 mediating the beneficial effects of beta-AR inverse agonists.

22 ible mechanism for the functional effects of inverse agonists.

23 Five of these molecules were inverse agonists.

24 classes: agonists, neutral antagonists, and inverse agonists.

25 ds, spanning the range of full, partial, and inverse agonists.

26 ding to a functional switch from agonists to inverse agonists.

27 ating the effect of cannabinoid CB1-receptor inverse agonists.

28 ith agonists and positive cooperativity with inverse agonists.

29 s TRPM3 responses can be potentiated by GPCR inverse agonists.

30 rol cellular acidification, in the manner of inverse agonists.

31 e binding modes of agonists, antagonists and inverse agonists.

32 agonized by CB1 and CB2 receptor antagonists/inverse agonists.

33 nities only CXCL12 and synthetic antagonists/inverse agonists.

34 are the first to demonstrate that RORgammat inverse agonists: 1) inhibit Tc17 cell differentiation,

35 ve state in the dark by the covalently bound inverse agonist 11-cis retinal.

36 Light transforms the inverse agonist 11-cis-retinal into the agonist all-tran

37 eceptor as it utilizes a covalently tethered inverse agonist (11-cis-retinal) as the native ligand.

38 would predict, we found that binding for the inverse agonist, 11-cis-retinal (11CR), slowed when the

39 K properties to afford the non-CNS penetrant inverse agonist 22 (AZ-GHS-22) and the CNS penetrant inv

40 the partial agonist arecoline (ARC), and the inverse agonist 3-quinuclidinyl-benzilate (QNB), in the

41 agonist 22 (AZ-GHS-22) and the CNS penetrant inverse agonist 38 (AZ-GHS-38).

42 ersed by coincubation with A(2A)AR-selective inverse agonist 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo

43 We generated a new CB1 inverse agonist, (4-(bis(4-fluorophenyl)methyl)piperazin

44 ve, some derivatives behave as mixed hA(1)AR inverse agonists/A(2A) and A(2B) AR antagonists.

45 e context-dependent antagonist, agonist, and inverse agonist activities.

46 o efficacy better than functional antagonist/inverse agonist activities.

47 novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1

48 de, DIIADDEPLT (Pep19), with slightly better inverse agonist activity at cannabinoid type 1 receptors

49 Seventeen compounds also possessed inverse agonist activity at the MC5R, the first report o

50 However, complete blockade or inverse agonist activity by some full mGlu5 NAM chemotyp

51 s and it was suggested that antagonists with inverse agonist activity could promote activation of mas

52 Inverse agonist activity of mant-dATP was found at the W

53 icity could be used to partially explain the inverse agonist activity of some members of the series,

54 old leads to ligands that exert an intrinsic inverse agonist activity on GHSR-catalyzed G protein act

55 n good overall yields and screened for their inverse agonist activity on the US28 receptor of human c

56 These results suggest SR141716A exerts inverse agonist activity through the stabilization of bo

57 , which switched partial agonist activity to inverse agonist activity, and optimized physicochemical

58 (mant-deoxy-ATP [dATP], mant-deoxy-ADP) with inverse agonist activity.

59 the mechanism by which SR141716A exerts its inverse agonist activity.

60 Notably, we found that these MT(1)-selective inverse agonists advanced the phase of the mouse circadi

61 d by enhanced agonist affinity and decreased inverse agonist affinity consistent with an active confo

62 ing hormone (alpha-MSH) and to an antagonist/inverse agonist, agouti-related peptide (AgRP), which ar

63 H3 receptor antagonists/inverse agonists also may be useful for treating cogniti

64 activation (agonist, neutral antagonist and inverse agonist) also stabilize distinct conformations o

65 diet-induced obese mice treated with the CB1 inverse agonist AM251 [1-(2,4-dichlorophenyl)-5-(4-iodop

66 The CB1 antagonist/inverse agonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iod

67 prevented by co-administration of the CB(2) inverse agonist AM630 (5 mg/kg, IP), but not the CB(1) i

68 new inhibitors, and the apparent bias toward inverse agonists among the docking hits, have implicatio

69 ded receptor as well as receptor bound to an inverse agonist, an agonist, and a G-protein-mimetic nan

70 A small-molecule inverse agonist and a neutral antagonist inhibited TSH-s

71 evealed key positions for the switch between inverse agonist and agonist response.

72 inopropane (DOI), antagonist ketanserin, and inverse agonist and antipsychotic drug clozapine.

73 receptor activity, indicating that it is an inverse agonist and that the ECD can negatively regulate

74 h G(s), as these complexes are stabilized by inverse agonists and receptor mutations that favor the i

75 eversed by prazosin, a selective alpha(1)-AR inverse agonist, and mimicked by chronically treating wi

76 k cancer cells in vitro, thus acting here as inverse agonists, and subsequent angiogenesis in vivo.

77 abinoid (CB1) receptor and exhibits a potent inverse agonist/antagonist activity.

78 3)R [pEC(50) (reporter gene) 8.77] and as an inverse agonist/antagonist at the h/mH(4)Rs [pIC(50) (re

79 .032-0.1 mg/kg/h, intravenous) or the 5-HT2A inverse agonist/antagonist pimavanserin (0.32-10 mg/kg p

80 monkeys with the cannabinoid CB(1) receptor inverse agonist/antagonist rimonabant [N-piperidino-5-(4

81 ell-investigated histamine H3 receptor (H3R) inverse agonist/antagonist, showing an exclusively high

82 inical utility of 5-HT2C agonists and 5-HT2A inverse agonists/antagonists alone or in combination as

83 Agonists of these receptors increased and inverse agonists/antagonists decreased cell-surface Glut

84 mpounds able to act either as agonists or as inverse agonists/antagonists were discovered.

85 Recently, several synthetic CB1 receptor inverse agonists/antagonists, such as SR141716A, AM251,

86 ults indicate that the effects of beta(2)-AR inverse agonists are caused by inhibition of beta(2)-AR

87 H1-receptor inverse agonists are used effectively for treating sever

88 Interestingly, all previously reported CAR inverse-agonists are also activators of PXR, rendering t

89 eptors (i.e., apo or bound to antagonists or inverse agonists) are poorly defined, despite the fact t

90 ected toward the discovery of selective RORc inverse agonists as potential treatments of inflammatory

91 novel histamine 3 receptor (H3R) antagonists/inverse agonists as treatment for such disorders.

92 zed [(3)H]RO6957022, a highly selective CB2R inverse agonist, as a radiolabeled tool compound.

93 VUF11211 acts as an inverse agonist at a constitutively active mutant of CXC

94 ound 17v is a potent (hH(3)R K(i) = 8.73 nM) inverse agonist at H(3)R with selectivity over other 70

95 -carboline-3-carboxamide (FG-7142; a partial inverse agonist at the benzodiazepine allosteric site on

96 a receptor-saturating dose of rimonabant, an inverse agonist at the CB(1) receptor.

97 allosteric site for rho-conopeptide TIA, an inverse agonist at this receptor.

98 riments, assessed that they behave as potent inverse agonists at the hA2A AR.

99 ng such mutants with the muscarinic receptor inverse agonist atropine increased cellular levels and r

100 etagamma interface, whereas it appears as an inverse agonist based on its SPR response thus indicatin

101 Consistent with inverse agonist behavior, increased cell surface localiz

102 kin-8), both classes of nanobodies displayed inverse agonist behavior.

103 Therefore, inverse agonists binding this site with high affinity ar

104 trinsic instability, as compared to inactive inverse agonist-bound states.

105 These studies show that unliganded and inverse-agonist-bound beta2AR exists predominantly in tw

106 beta2-adrenergic receptor (beta2AR): 1), the inverse-agonist-bound inactive state; 2), the agonist-bo

107 conformational heterogeneity in agonist- and inverse-agonist-bound preparations.

108 lated persistent IP1 production, whereas the inverse agonist but not the neutral antagonist inhibited

109 le for docking of a range of antagonists and inverse agonists but also indicate that additional ligan

110 been determined in complex with two partial inverse agonists, but the global impact of additional li

111 Ethylene acts as an inverse agonist by inhibiting its receptors, resulting i

112 ducing signaling by empty receptors, beta-AR inverse agonists can also activate signaling by novel pa

113 For many of these GPCRs, drugs classified as inverse agonists can suppress basal activity.

114 tive and inactive state conformations, while inverse agonist carazolol selects only inactive state co

115 man beta(2) adrenergic receptor bound to the inverse agonist carazolol using the technique of amide h

116 isplayed differential binding preference for inverse agonists comparable with the P269A, H270A, and I

117 Administration of rimonabant (CB1 inverse agonist) completely abrogated the effect of mTBI

118 his population was attenuated by a RORgammat inverse agonist compound and clinically relevant therape

119 absence of agonist, the aggregators acted as inverse agonists, consistent with a direct receptor inte

120 ein (AgRP), an MC3R/MC4R antagonist and MC4R inverse agonist, contains an exposed beta-hairpin loop c

121 r-activated receptor gamma (PPARgamma) in an inverse agonist/corepressor-bound transcriptionally repr

122 Mutational screening in the presence of the inverse agonist, CP-376395, resulted in the identificati

123 ired continuously activated receptors, as an inverse agonist decreased persistent signaling by 60%.

124 for very short times or the addition of the inverse agonist did not significantly affect the organiz

125 ization, selective agonists, antagonists and inverse agonists, dimerization with other neurotransmitt

126 Muscarinic M(3) receptor antagonists and inverse agonists displaying high affinity and subtype se

127 d-bound RORgammat reveal that binding of the inverse agonists disrupts critical interactions that sta

128 radoxical hypothesis that the alpha-receptor inverse agonist doxazosin might produce beneficial effec

129 also decreases basal signaling, acting as an inverse agonist for the G protein-mediated signaling pat

130 syntheses of two magic methyl substrates-an inverse agonist for the nuclear receptor RORc and an ant

131 2c) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.

132 we previously identified several classes of inverse agonists for RORgammat.

133 activation is elevated and sensitive to the inverse agonist, GR113808 in the PFC of CK2alpha KO mice

134 The RORC inverse agonist GSK805, but not antibodies against IL17A

135 ship, several potent and selective RORgammat inverse agonists have been identified.

136 CB2R agonists and inverse agonists have emerged as neuroprotective agents,

137 H3 receptor inverse agonists (IAs) may be efficacious in the treatme

138 ve suppression of beta2-AR basal activity by inverse agonist ICI 118,551 requires ionic interactions

139 The inverse agonist ICI prevents formation of the beta(2)AR-

140 ve-like conformation, whereas binding of the inverse agonist ICI-118,551 favors the inactive conforma

141 ered beta(2)AR construct in complex with two inverse agonists: ICI 118,551 (2.8 A), a recently descri

142 erestingly, AGN211334 behaved as an apparent inverse agonist in CDS assays involving TM cells but as

143 The antagonist BD1063 behaved as an inverse agonist in sigma-1R cells, whereas C-fragment wa

144 previously explored chemotypes-that acted as inverse agonists in a mouse model of circadian re-entrai

145 low intrinsic level of the MOP receptor were inverse agonists in reducing the greater level of consti

146 ential of SR1001, a synthetic RORalpha/gamma inverse agonist, in mouse models of atopic dermatitis an

147 f pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population.

148 In contrast, the inverse agonist increases the frequency of deactivation

149 d with nonpeptide ligand signaling activity; inverse agonists inhibited and agonists enhanced CRF bin

150 Agonists and inverse agonists interact differentially with these path

151 This efficient inverse agonist is rapidly converted to an agonist, the

152 tivation and inhibition of basal activity by inverse agonists is poorly understood and difficult to s

153 f this basal activity and its suppression by inverse agonists is unknown but could involve a unique r

154 tantly, CB1b shows stronger affinity for the inverse agonist JD-5037 than for rimonabant compared to

155 id receptor 2 antagonist AM630 (10 mg/kg) or inverse agonist JTE907 (3 mg/kg) during immunization hei

156 inding studies showed a high affinity of the inverse agonist K-(d-1-Nal)-FwLL-NH(2) at the ghrelin re

157 ession of MOR constitutive activity with the inverse agonist KC-2-009 enhanced GABAergic neurotransmi

158 onist 5-HT, the partial agonist LSD, and the inverse agonist Ketanserin.

159 ication of the alpha5 subunit GABAA receptor inverse agonist L-655,708 did not modulate the current.

160 In contrast, binding of inverse agonists leads to significant increases in FRET

161 B2 in complex with a new rationally designed inverse agonist (Li et al., 2019) provide unique snapsho

162 Therefore, an inverse agonist ligand capable of selectively targeting

163 -coupled receptor (GPCR) that stabilizes its inverse agonist ligand, 11-cis-retinal (11CR), by a cova

164 ng of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the a

165 Our results imply that LXR inverse agonists may be a promising new class of TNBC im

166 Our results suggest that LXR inverse agonists may be an effective cancer treatment ap

167 ibiting the NLRP3 inflammasome with RORgamma inverse agonists may be an effective method to treat NLR

168 evated basal activity in vitro, and as such, inverse agonists may be therapeutically beneficial compa

169 Therefore, beta-AR inverse agonists may produce their beneficial chronic ef

170 rs, specifically beta-adrenoceptor (beta-AR) inverse agonists, may be useful in the chronic treatment

171 d with the arrestin-biased ligand LSD or the inverse agonist methiothepin.

172 In contrast, the inverse agonist metoprolol suppresses interactions with

173 Thus, inverse agonists might prove to be effective therapies f

174 Overall, these novel inverse agonists might represent potential drug candidat

175 This is similar to the inverse-agonist model of ethylene receptor signaling pro

176 lity in the discovery of new antagonists and inverse agonists modulating signaling of this important

177 f any complete aGPCR ECR, in complex with an inverse-agonist monobody, revealing a GPCR-Autoproteolys

178 roxypropyl)cyclohe xan-1-ol (CP55940) or the inverse agonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-

179 ys, ORG27569 can displace the CB1 antagonist/inverse agonist, N-(piperidiny-1-yl)-5-(4-chlorophenyl)-

180 en given the preferential mu-opioid receptor inverse agonist naloxone, suggesting the participation o

181 duced hyperalgesia was reinstated by the MOR inverse agonist naltrexone (NTX), but not by its neutral

182 ARBs, including olmesartan derivatives with inverse agonist, neutral antagonist, or agonist activiti

183 Treatment with an RARgamma-selective inverse agonist (NRX205099) or overexpression of dominan

184 (IOM; 3.7 mug/kg), an antagonist and partial inverse agonist of benzodiazepine receptor.

185 of CB1 have largely targeted rimonabant, an inverse agonist of CB1.

186 ntrasubthalamic microinjections of either an inverse agonist of D5Rs, flupenthixol, or a D2R antagoni

187 S 38093, a novel brain-penetrant antagonist/inverse agonist of H3 receptors, on AHN (proliferation,

188 on of a mouse Sertoli cell line, TM4, and an inverse agonist of PPARD (DG172) rescued this effect.

189 iously, it was shown that the small molecule inverse agonist of RORgamma SR1555 [1-(4-((4'-(1,1,1,3,3

190 n antagonist ligand, AIP-II, functions as an inverse agonist of the kinase activity.

191 prove wakefulness by acting as an antagonist/inverse agonist of the presynaptic histamine 3 receptor.

192 Candesartan, an inverse agonist of the type 1 angiotensin II receptor (A

193 arkinson's disease and that administering an inverse agonist of these receptors may lessen motor symp

194 Drugs that act as inverse agonists of cannabinoid CB1 receptors in the bra

195 Some inverse agonists of cannabinoid receptor type 1 (CB1) ha

196 Inverse agonists of CB(1)R (SR141716 and AM251) and inhi

197 ysfunction and degeneration of rods, whereas inverse agonists of ERRbeta trigger rapid rod degenerati

198 both LEAP2 and its N-terminal part behave as inverse agonists of GHSR and as competitive antagonists

199 pment of several highly potent and selective inverse agonists of GHSR based on the 1,2,4-triazole sca

200 compounds have been produced that are potent inverse agonists of hCB1 with exceptional selectivity fo

201 Only a few inverse agonists of P2Y(12) have been described.

202 OH)D3 and 20,23(OH)2D3 act as antagonists or inverse agonists of RORalpha and RORgamma, that opens ne

203 nazolines] that were found to be antagonists/inverse agonists of the alpha2-adrenoceptor.

204 ical role in the control of food intake, and inverse agonists of the ghrelin receptor (GHS-R1a) are w

205 ifluorophenyl)ur ea (Nelotanserin), a potent inverse-agonist of 5-HT(2A) that was advanced into clini

206 ation of sleep architecture, and antagonists/inverse-agonists of 5-HT(2A) have been shown to enhance

207 ructure of the human AT1R in complex with an inverse agonist olmesartan (Benicar(TM)), a highly poten

208 ts as an antagonist, whereas BCML acts as an inverse agonist on T2R4.

209 herein describe a series of phenyl pyrazole inverse agonists optimized for selectivity, aqueous solu

210 ly, while the chemokine CX3CL1 behaves as an inverse agonist or inhibitor of constitutive US28 signal

211 al APDs are also effective 5-HT(2C) receptor inverse agonists or neutral antagonists, 5-HT(6) or 5-HT

212 ical development of the centrally acting CB1 inverse agonist otenabant (1) was halted due to its pote

213 yl)-4-methyl-3-pyrazole carboxamide] (CB(1)R inverse agonist) paradigms, mutants display normal body

214 Binding of agonist or inverse-agonist peptides results in twisting of the link

215 ety and tolerability of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alc

216 havioral effects of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with a

217 vivo where Gi/o GPCRs agonists inhibited and inverse agonists potentiated TRPM3 mediated nociceptive

218 intaining a potent and highly selective RORc inverse agonist profile.

219 igh to good human (h) A(1)AR affinity and an inverse agonist profile.

220 generation of useful SAR during a RORgammat inverse agonist program.

221 ration of alprenolol, a beta-blocker without inverse agonist properties, did not attenuate the asthma

222 aken together, indicate that this allosteric inverse agonist radioligand for CXCR3 may facilitate the

223 studied using PET with [(11)C]MePPEP, a CB1 inverse agonist radioligand.

224 understanding of structural determinants of inverse agonist-receptor interaction, this study screene

225 Additionally, RORgamma inverse agonists reduced mortality in an LPS/d-galactosa

226 systemic administration of a 5-HT6 receptor inverse agonist reduces CREB phosphorylation in prefront

227 n and gene expression, whereas others act as inverse agonists reducing biofilm formation and antibiot

228 e during the posthyperalgesia state with MOR inverse agonists reinstated central pain sensitization a

229 es the molecular mechanism of action for the inverse agonists reported here.

230 However, the first generation of CB1 inverse agonists, represented by rimonabant (SR141716A),

231 we describe a novel series of selective CB2 inverse agonists resulting from introduction of a methox

232 have found that administration of beta(2)-AR inverse agonists results in attenuation of the asthma ph

233 onist AM630 (5 mg/kg, IP), but not the CB(1) inverse agonist rimonabant (1 mg/kg, IP).

234 following administration of the cannabinoid inverse agonist rimonabant (150 mug/kg, i.v).

235 ment in squirrel monkeys by the CB1-receptor inverse agonist rimonabant and by the recently developed

236 t this system using the cannabinoid receptor inverse agonist rimonabant were successful in producing

237 Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease

238 as prevented by co-administration of the CB1 inverse agonist rimonabant.

239 (2)R have been described in complex with the inverse agonists risperidone (D(2)R(ris)) and haloperido

240 inhibited by the 5-HT(2C) receptor-specific inverse agonist SB-243213, and were absent in MT(2) and

241 be displaced by the 5-HT7 receptor selective inverse agonist SB-269970.

242 in but also by the CXCR2-specific allosteric inverse agonist SB265610.

243 on, we administered in vivo a benzodiazepine inverse agonist specific for alpha5-subunit-containing e

244 Moreover, treatment with a RORalpha inverse agonist SR1001 effectively protected against pat

245 ed by a cannabinoid receptor type 1 (CB(1)R) inverse agonist (SR141716), and by clodronate-induced my

246 B1 cannabinoid receptors with the antagonist/inverse agonist SR141716A prevented the play-enhancing e

247 cooperativity and inhibiting binding of the inverse agonist SR141716A with negative cooperativity, d

248 ished binding for several agonists but bound inverse agonists SR141716A, N-(piperidin-1-yl)-5-(4-iodo

249 ma, and extend these findings to develop the inverse agonist SR2595.

250 enic metabolism pathways, we designed an LXR inverse agonist SR9243 that induces LXR-corepressor inte

251 f histamine H(3) receptor (H(3)R) antagonist/inverse agonist structures, partial or full H(3)R agonis

252 a mechanism for the inhibition of gating by inverse agonists such as bicuculline.

253 RORgamma inverse agonists suppressed lipopolysaccharide (LPS)/ATP

254 Binding of inverse agonists suppresses this population.

255 agonist (ZM241385) bound receptors, with the inverse agonist suppressing fast ps-ns timescale motions

256 anism of action of the corepressor-selective inverse agonist T0070907, and reveals that apo-helix 12

257 ion with Rev-Erbalpha or addition of the ROR inverse agonist T0901317.

258 d by grafting the CXCL12 N-terminus onto the inverse agonist T140.

259 ituted flavonoids were typically more potent inverse agonists than their related hydro derivatives.

260 12c was found to be a highly selective CB1R inverse agonist that reduced body weight and food intake

261 able, highly efficacious, and selective CB1R inverse agonists that caused food intake suppression and

262 We describe here a series of 5-HT(2A) inverse-agonists that when dosed in rats, both consolida

263 In the presence of inverse agonists, the conformation of ECL2 in the N111G

264 nd the potential therapeutic applications of inverse agonists, the molecular mechanisms underlying G

265 C terminus of EC2 differentiates agonist and inverse agonist; the P269A, H270A, and I271A receptors e

266 s new opportunities for developing novel CB1 inverse agonists through the optimization of molecular p

267 5-HT(2A) receptor inverse agonists thus represent a potential new class of

268 e of the M3 receptor bound by the antagonist/inverse agonist tiotropium were then employed.

269 M1 and M4 muscarinic receptors bound to the inverse agonist, tiotropium.

270 ibe a novel, potent, and selective RORgammat inverse agonist (TMP778), and its inactive diastereomer

271 oughout the activation cycle, switching from inverse agonist to agonist after absorbing a photon.

272 Furthermore, the ability of 5-HT(2A) inverse agonists to normalize behavioral changes induced

273 Additionally, the ability of the RORgamma inverse agonists to suppress IL-1beta secretion was lost

274 ll molecule ghrelin receptor antagonists and inverse agonists to the clinic.

275 (2) antagonist, and pimavanserin, a 5-HT(2A) inverse agonist, to prevent the development of the PCP-i

276 Notably, the V2R-selective inverse agonists tolvaptan and satavaptan completely sil

277 identified some ligands that were selective inverse agonists toward Gq but not of G13.

278 to what was observed with chronic beta(2)-AR inverse agonist treatment, namely, reductions in mucous

279 ptor rationalized the pharmacology observed; inverse agonists, unlike neutral antagonists, cannot be

280 Their in vitro functional activity as inverse agonists was confirmed in vivo in the formalin t

281 s as selective cannabinoid-1 receptor (CB1R) inverse agonists was discovered through high throughput

282 he NLRP3 inflammasome in vivo using RORgamma inverse agonists was examined in two models: LPS-induced

283 To determine the mechanism of the beta-AR inverse agonists, we compared the asthma phenotype in be

284 RORgamma inverse agonists were effective inhibitors of the inflam

285 on 2 resulted in highly potent and efficient inverse agonists, whereas the substitution of d-tryptoph

286 074, a potent and highly-selective RORgammat inverse agonist, which dose-dependently inhibited RORgam

287 ased optimization led to two selective MT(1) inverse agonists-which were topologically unrelated to p

288 Hence, the discovery of CB1 inverse agonists with a chemical scaffold distinct from

289 the discovery of novel allosteric RORgammat inverse agonists with a distinct isoxazole chemotype.

290 ose a general binding mode for this class of inverse agonists with CB2.

291 omise for developing peripherally active CB1 inverse agonists with fewer side effects.

292 eight compounds as potent and selective CB2 inverse agonists with high binding affinity (CB2K(i) < 1

293 ion of a novel series of tricyclic RORgammat inverse agonists with significantly improved in vitro ac

294 s were developed and also confirmed as CB(2) inverse agonists with the highest CB(2) binding affinity

295 erence to bind to the active state receptor; inverse agonists (xanthine amine congener, ZM241385, SCH

296 In contrast, the inverse agonist ZM241385 does not interact with any of t

297 ation conferred on the receptor by the bound inverse agonist ZM241385.

298 hion to the chemically related region of the inverse agonist ZM241385.

299 acts with cholesterol only when bound to the inverse agonist ZM241385.

300 stantially differ between agonist (NECA) and inverse agonist (ZM241385) bound receptors, with the inv